Fondaparinux Sodium is the sodium salt form of fondaparinux, a synthetic glucopyranoside with antithrombotic activity. Fondaparinux sodium selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. It is grouped under the following drug class(es): Antithrombotic agents and Carbohydrates. Its therapeutic use is listed as anticoagulants, cardiovascular and hematologic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Arixtra, Quixidar and Xantidar. Its PubChem CID is 636380.
Fondaparinux sodium
| CAS No | 114870-03-0 |
|---|---|
| Molecular Formula | C31H43N3Na10O49S8 |
| Molecular Weight | 1728.10 g/mol |
| Synonyms | decasodium;(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fondaparinux Sodium is the sodium salt form of fondaparinux, a synthetic glucopyranoside with antithrombotic activity. Fondaparinux sodium selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin.
The listed CAS number is 114870-03-0.
The listed molecular formula is C31H43N3Na10O49S8.
The listed molecular weight is 1728.10 g/mol.
The source lists Arixtra, Quixidar and Xantidar.
Its therapeutic use is listed as anticoagulants, cardiovascular and hematologic agents.